KNSA Kiniksa Pharmaceuticals International, plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1730430 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY58.2%
TTM net income YoY205.1%
TTM EPS YoY193.3%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—
Margins
Gross margin90.2%
Operating margin13.8%
Net margin11.6%
FCF margin20.8%
EBITDA margin13.9%
Returns
ROE17.6%
ROA12.9%
ROIC (approx.)19.8%
Asset turnover1.12x
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $677.56M | $423.24M |
| Cost of revenue | $77.67M | $60.91M |
| Gross profit | $599.89M | $362.33M |
| R&D expense | $96.85M | $111.62M |
| SG&A expense | $196.27M | $168.01M |
| Operating income | $77.22M | -$45.62M |
| Pretax income | $88.87M | -$36.15M |
| Income tax | $29.86M | $7.04M |
| Net income | $59.01M | -$43.19M |
| EBITDA | $78.78M | -$43.92M |
| EPS (basic) | 0.80 | -0.60 |
| EPS (diluted) | 0.75 | -0.60 |
| Weighted avg. shares (diluted) | 78.98M | 71.42M |
| Balance sheet | ||
| Cash & equivalents | $165.60M | $183.58M |
| Short-term investments | $248.48M | $60.05M |
| Receivables | $15.59M | $41.72M |
| Inventory | $54.90M | $26.36M |
| Current assets | $527.18M | $331.80M |
| PP&E, net | $1.94M | $662,000 |
| Intangibles | $15.25M | $16.25M |
| Total assets | $763.63M | $580.55M |
| Current liabilities | $139.18M | $100.62M |
| Total liabilities | $196.03M | $142.12M |
| Shareholders' equity | $567.61M | $438.44M |
| Cash flow statement | ||
| Operating cash flow | $137.99M | $25.69M |
| Capital expenditure | $1.57M | $277,000 |
| Free cash flow | $136.42M | $25.41M |
| Investing cash flow | -$188.99M | $37.67M |
| Financing cash flow | $33.02M | $12.27M |
| Depreciation & amortization | $1.55M | $1.70M |
| Stock-based compensation | $37.00M | $30.69M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.